Bulk Pharmaceutical API Sources for ponesimod

Bulk Pharmaceutical API Sources for ponesimod

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS022180266
A&J Pharmtech CO., LTD.		AJ-89002
MolPort		MolPort-035-681-391
BOC Sciences		854107-55-4

Ponesimod Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This analysis identifies key bulk Active Pharmaceutical Ingredient (API) sources for ponesimod, a sphingosine-1-phosphate receptor 1 (S1P1) modulator used in the treatment of relapsing forms of multiple sclerosis. The focus is on identifying manufacturers with established production capabilities and regulatory compliance necessary for pharmaceutical supply chains.

What is Ponesimod API?

Ponesimod API, chemically known as 2-[2-[1-(4-ethylphenyl)-2-(3-methyl-1H-inden-2-yl)ethyl]phenoxy]-N-(methylsulfonyl)ethanamine, is the active pharmaceutical ingredient in the drug ponesimod. Its mechanism of action involves selectively binding to and activating the S1P1 receptor. This activation leads to the internalization of S1P1 receptors on lymphocytes, reducing their egress from secondary lymphoid organs into circulation. This sequestration of lymphocytes is believed to be the primary mechanism by which ponesimod exerts its therapeutic effect in multiple sclerosis by limiting inflammatory cell infiltration into the central nervous system.

The synthesis of ponesimod API is a multi-step process requiring specialized chemical expertise and controlled manufacturing environments. Key considerations for API sourcing include the purity profile, enantiomeric excess, particle size distribution, and the absence of residual solvents or heavy metals, all of which are critical for drug product efficacy and patient safety. Regulatory compliance, including Good Manufacturing Practices (GMP), is paramount for any API supplier.

Key Ponesimod API Manufacturers and Suppliers

Several entities are involved in the production or supply of ponesimod API. Identification of these sources is crucial for supply chain security, cost negotiation, and risk mitigation.

Contract Development and Manufacturing Organizations (CDMOs)

CDMOs play a significant role in the pharmaceutical API landscape, offering specialized manufacturing services. For ponesimod, CDMOs with expertise in complex organic synthesis and GMP-compliant facilities are primary sources.

• Lonza Group AG: Lonza is a well-established CDMO with a broad range of services, including small molecule API manufacturing. They operate significant GMP-compliant manufacturing sites globally. Their capabilities in complex chemistry and large-scale production make them a potential supplier for ponesimod. Lonza has experience in producing APIs for various therapeutic areas and adheres to stringent regulatory standards from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Catalent, Inc.: Catalent is another major CDMO providing drug substance development and manufacturing. They possess expertise in complex synthesis and have a global network of facilities capable of GMP production. Their integrated services can support ponesimod API development from early-stage to commercial supply. Catalent's regulatory track record and experience with multiple drug approvals are advantageous.
• Thermo Fisher Scientific Inc.: While broadly known for its laboratory products, Thermo Fisher also offers custom manufacturing services for APIs through its pharmaceutical sciences division. They operate GMP-certified facilities and can handle complex chemical synthesis. Their involvement would likely be through their Contract Development and Manufacturing Services segment.

In-House Manufacturing by Innovator Companies

The innovator company, typically responsible for drug discovery and development, may also maintain in-house manufacturing capabilities for critical APIs like ponesimod. This ensures tighter control over the supply chain and intellectual property.

• Idorsia Pharmaceuticals Ltd.: Idorsia Pharmaceuticals is the originating company that developed ponesimod. While they may utilize CDMOs for certain aspects of production or to scale up, they likely possess or have direct oversight of the primary manufacturing processes for ponesimod API to ensure quality and supply chain integrity. Information regarding their specific API manufacturing sites is often proprietary.

Generic API Manufacturers

As ponesimod's patent landscape evolves, generic API manufacturers may emerge. However, for a relatively recent drug like ponesimod, the primary sources for bulk API will initially be linked to the innovator's supply chain or established CDMOs. Generic API manufacturers would typically enter the market post-patent expiry or through licensing agreements.

• Emerging Generic API Manufacturers: Companies based in India and China are significant players in the generic API market. Manufacturers such as Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Ltd. are examples of large-scale API producers with GMP compliance. For ponesimod, these companies would require specific process patents or rely on publicly available synthesis routes to develop their own manufacturing processes. Their entry is contingent on patent exclusivity periods.

Regulatory Landscape and Quality Assurance

The sourcing of ponesimod API is governed by strict regulatory requirements to ensure patient safety and product efficacy.

Good Manufacturing Practices (GMP)

All manufacturers of ponesimod API must adhere to GMP guidelines. These regulations, enforced by agencies like the FDA, EMA, and others, ensure that APIs are consistently produced and controlled according to quality standards. Key aspects of GMP compliance include:

• Quality Management Systems: Robust systems for documentation, change control, deviations, and investigations.
• Facility and Equipment: Appropriately designed, maintained, and qualified facilities and equipment.
• Personnel: Adequately trained and qualified personnel.
• Process Validation: Demonstrating that the manufacturing process consistently yields API meeting predefined specifications.
• Analytical Testing: Rigorous testing of raw materials, intermediates, and the final API for identity, purity, strength, and quality.

Drug Master Files (DMFs)

API manufacturers typically submit Drug Master Files (DMFs) to regulatory authorities. A DMF is a submission to a regulatory agency (e.g., FDA) that provides detailed information about the manufacturing process, facilities, and quality controls used in the production of a drug substance. This allows the regulatory agency to review the API information in support of a drug product application without disclosing proprietary information to the drug product applicant.

• FDA DMFs: Manufacturers can file Type II DMFs for drug substances with the FDA. These are accessible to the FDA reviewers during the review of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).
• European DMFs (EDMFs) / Active Substance Master Files (ASMFs): Similar to FDA DMFs, these allow confidential information about the API to be shared with regulatory authorities.

The availability and acceptance of a DMF are critical for a ponesimod API supplier to be considered by drug product manufacturers.

Supply Chain Considerations and Risk Mitigation

Securing a reliable supply of ponesimod API involves navigating several considerations.

Geographic Diversification

Relying on a single manufacturing site or geographic region for ponesimod API poses risks related to geopolitical instability, natural disasters, or localized regulatory changes. Diversifying the supplier base across different regions (e.g., North America, Europe, Asia) can enhance supply chain resilience.

Redundancy and Dual Sourcing

For critical APIs like ponesimod, establishing relationships with at least two qualified suppliers can provide redundancy. Dual sourcing mitigates risks associated with a single supplier's production issues, quality failures, or unexpected capacity constraints.

Intellectual Property (IP) Landscape

Understanding the patent status of ponesimod and its manufacturing processes is essential. Innovator companies typically hold patents on the compound itself and potentially on specific synthetic routes. Generic API manufacturers must navigate this IP landscape to avoid infringement.

• Compound Patents: These protect the ponesimod molecule itself.
• Process Patents: These protect specific methods of synthesizing ponesimod.

Companies seeking to source ponesimod API must conduct thorough due diligence regarding the IP status of their chosen suppliers' manufacturing processes.

Lead Times and Capacity

The lead time for API production can be substantial, ranging from months to over a year, depending on the complexity of the synthesis and the supplier's existing commitments. It is crucial to assess supplier capacity to meet projected demand and to secure supply agreements well in advance of anticipated needs.

Cost and Negotiation

API costs represent a significant portion of the overall drug product manufacturing cost. Negotiating favorable pricing requires understanding market dynamics, competitor pricing (if applicable), and the supplier's cost structure. Factors influencing API cost include:

• Raw material costs
• Complexity of the synthesis
• Scale of production
• Regulatory compliance costs
• Yields of each synthetic step

Quality Audits

Conducting regular quality audits of API manufacturers is a standard practice in the pharmaceutical industry. These audits verify ongoing compliance with GMP and assess the manufacturer's quality systems. They provide an opportunity to identify potential issues before they impact API quality or supply.

Ponesimod API Sourcing Strategy Recommendations

Based on the analysis of available information, the following strategic recommendations can guide ponesimod API sourcing decisions:

1. Prioritize GMP-Certified and Audited Suppliers: Engage with CDMOs and API manufacturers with a demonstrable history of GMP compliance, successful regulatory inspections, and a strong quality management system.
2. Evaluate Supply Chain Resilience: Assess the geographic location of manufacturing facilities and the supplier's business continuity plans. Consider dual sourcing from geographically diverse locations for critical supply needs.
3. Conduct Thorough Due Diligence: This includes reviewing DMFs, site inspection reports, and the supplier's financial stability. For generic API sourcing, a detailed analysis of the IP landscape surrounding manufacturing processes is imperative.
4. Establish Long-Term Agreements: Secure long-term supply agreements that clearly define quality specifications, delivery schedules, pricing mechanisms, and change control procedures to ensure predictable supply and cost.
5. Monitor Regulatory Updates: Stay abreast of any changes in regulatory requirements or guidance that could impact API sourcing or manufacturing standards for ponesimod.

Key Takeaways

• Ponesimod API sourcing primarily relies on established Contract Development and Manufacturing Organizations (CDMOs) with expertise in complex organic synthesis and GMP compliance.
• Innovator companies like Idorsia Pharmaceuticals Ltd. may maintain direct control over critical API manufacturing.
• Regulatory compliance, particularly adherence to Good Manufacturing Practices (GMP) and the submission of comprehensive Drug Master Files (DMFs), is non-negotiable for API suppliers.
• Supply chain resilience can be enhanced through geographic diversification and dual sourcing strategies.
• A thorough understanding of the intellectual property landscape is critical, especially for generic API development and sourcing.

Frequently Asked Questions

1. What are the primary regulatory requirements for ponesimod API manufacturers? Ponesimod API manufacturers must adhere to Good Manufacturing Practices (GMP) as mandated by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes rigorous quality control, process validation, facility compliance, and robust documentation.

2. How can a company ensure the quality and consistency of ponesimod API from external suppliers? Companies can ensure API quality through several methods: conducting thorough due diligence on potential suppliers, reviewing their regulatory track record and quality systems, performing site audits, and establishing stringent quality agreements that define specifications and testing protocols. The review of submitted Drug Master Files (DMFs) is also a critical step.

3. What is the typical lead time for securing bulk ponesimod API? The lead time for bulk ponesimod API can vary significantly but often ranges from six months to over a year. This duration depends on the complexity of the synthesis, the supplier's current production capacity, raw material availability, and the scale of the order.

4. What are the potential risks associated with relying on a single source for ponesimod API? Relying on a single source for ponesimod API exposes a company to significant risks, including supply disruptions due to manufacturing issues, quality failures, natural disasters, geopolitical instability, or unexpected changes in the supplier's business operations or regulatory standing.

5. Where can I find publicly available information on ponesimod API manufacturing processes? Detailed, proprietary manufacturing processes for ponesimod API are typically confidential. However, some information might be inferable from patent literature (e.g., U.S. Patents, European Patents) related to the synthesis of ponesimod or its intermediates. Regulatory filings, such as Drug Master Files (DMFs), contain extensive detail but are generally not made public.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website] (Specific URL not provided as it is a general information page) [2] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from [EMA website] (Specific URL not provided as it is a general information page) [3] Idorsia Pharmaceuticals Ltd. (2024). Idorsia at a glance. Retrieved from [Idorsia website] (Specific URL not provided as it is a general company information page) [4] Lonza Group AG. (2024). Small Molecules. Retrieved from [Lonza website] (Specific URL not provided as it is a general service page) [5] Catalent, Inc. (2024). Drug Substance Manufacturing. Retrieved from [Catalent website] (Specific URL not provided as it is a general service page)